what does retatrutide peptide do How works: mechanism of action and onset explained What Is Retatrutide? | Research-Use

For someone who has obesity, type 2 diabetes, or cardiovascular risk factors, a prescription GLP-1 medication could meaningfully reduce their health risks

If Foundayo's clinical outcomes hold up in real-world use (the Phase 3 ATTAIN-1 trial showed 11.2% mean weight loss at 72 weeks on the 36 mg dose, or 12.4% among participants who stayed on treatment), it could become the go-to affordable GLP-1 option and put downward pressure on Wegovy and Zepbound pricing

doi: 10.1056/NEJMoa2404881 34

Moving from insulin to GLP-1 A patient on basal insulin whose Type 2 diabetes is relatively well controlled might transition to a GLP-1 agonist if they are gaining excessive weight on insulin, want to simplify their regimen, have developed cardiovascular risk factors that would benefit from GLP-1 protection, or have adequate remaining beta cell function

These gastrointestinal side effects typically peak during weeks 6-8 and resolve significantly by week 12

Novak P, Pimentel Maldonado DA, Novak V